{"id":14389,"date":"2011-02-01T09:58:15","date_gmt":"2011-02-01T09:58:15","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=14389"},"modified":"2013-01-30T13:13:02","modified_gmt":"2013-01-30T13:13:02","slug":"arvs-and-targeted-cancer-therapies","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/14389","title":{"rendered":"ARVs and targeted cancer therapies"},"content":{"rendered":"<p><strong><a href=\"http:\/\/www.hiv-druginteractions.org\">HIV-druginteractions.org<\/a><\/strong><\/p>\n<p>This news item highlights the challenge of administering both the new cancer therapies and antiretroviral drugs. [1]<\/p>\n<p>In 2009 John Deeken and colleagues presented an overview of the disposition of the targeted anticancer drugs imatinib, dasatinib, nilotinib, erlotinib, bortezomib, sorafenib, temsirolimus, sunitanib and lapatinib and suggested the potential for marked drug-drug interactions with some antiretrovirals. [2]<\/p>\n<p>In the present news item, there is mention of an on ongoing trial between sunitinib and a) a boosted PI and b) efavirenz.\u00a0 The AIDS Malignancy Consortium at the NCI is now planning investigation of interactions with at least three other cancer drugs \u0096 vorinostat, sorasenib and dasatinib.\u00a0 The bottom line is that there is an urgent need to define drug-drug interactions for HIV and cancer.<\/p>\n<p>References:<\/p>\n<ol>\n<li>Schmidt C.\u00a0The cancer-HIV\/AIDS treatment conundrum.\u00a0J Nat Cancer Institute, 2010,\u00a0102(21): 1615-1617.<br \/>\n<a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20966428\">http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20966428<\/a><\/li>\n<li>Deakin JF et al.\u00a0Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook.\u00a0Curr Opin Oncol. 2009 Sep;21(5):445-54.<br \/>\n<a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19606034\">http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19606034<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>HIV-druginteractions.org This news item highlights the challenge of administering both the new cancer therapies and antiretroviral drugs. [1] In 2009 John Deeken and colleagues presented an overview of the disposition of the targeted anticancer drugs imatinib, dasatinib, nilotinib, erlotinib, bortezomib, &hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[],"class_list":["post-14389","post","type-post","status-publish","format-standard","hentry","category-pk-and-drug-interactions"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/14389","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=14389"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/14389\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=14389"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=14389"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=14389"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}